A striking number of Americans without an obesity or diabetes diagnosis are now taking GLP-1 medications originally developed for those conditions. According to a large-scale study of over 2.4 million patients prescribed GLP-1 receptor agonists between 2018 and 2025, roughly one in four first-time users did not carry a type 2 diabetes diagnosis — a signal that weight loss, not medical necessity, is driving a significant share of new prescriptions. For families navigating dementia care and brain health, this trend raises pointed questions: what happens when widely prescribed drugs with poorly understood long-term effects enter the medicine cabinets of people who may not need them, including older adults already managing cognitive decline? The shift has been rapid. By 2026, nearly one in five U.S.
adults has tried a GLP-1 medication, and about one in eight remains an active user. A growing cohort of younger adults aged 18 to 39 are seeking these drugs through telehealth platforms and private clinics for appearance-focused weight loss, often outside traditional guideline-based criteria. Meanwhile, both Novo Nordisk and Eli Lilly have dropped specific BMI ranges from their FDA labels for Wegovy and Zepbound, leaving only vague references to “obese and overweight patients” — a move that effectively broadens who can be prescribed these drugs. This article examines what this expansion means for patients without obesity, the risks that come with off-label or borderline use, and why caregivers and older adults should pay close attention to a drug class whose long-term consequences remain largely unstudied.
Table of Contents
- Who Is Using Weight Loss Drugs Without an Obesity Diagnosis, and Why?
- How Loosened Prescribing Standards Are Fueling Off-Label Use
- The Muscle Loss Problem and Why It Matters for Brain Health
- Insurance Barriers, Cost Pressures, and the Access Paradox
- Disordered Eating, Screening Gaps, and Unmonitored Side Effects
- Tirzepatide Versus Semaglutide — What the Head-to-Head Data Shows
- What This Trend Means for Dementia Care Going Forward
- Conclusion
- Frequently Asked Questions
Who Is Using Weight Loss Drugs Without an Obesity Diagnosis, and Why?
The profile of the typical new GLP-1 user has shifted considerably. A study of 33,607 insured patients without diabetes who started GLP-1 treatment found that 75.5 percent were female, with a mean age of 45.7 years. But age and gender only tell part of the story. Online sellers and compounding pharmacies have made it relatively simple to obtain a prescription for people who do not meet formal medical criteria for obesity. A person with a BMI of 27 — classified as overweight but not obese — can often secure a prescription through a brief telehealth consultation, bypassing the kind of thorough screening that would happen in a primary care office. The motivation for many of these patients is cosmetic rather than clinical.
The DDW reported that a growing number of adults aged 18 to 39 are pursuing GLP-1s for aesthetic reasons, seeking prescriptions through platforms that prioritize convenience over comprehensive evaluation. Compare this to the patient population these drugs were designed for: individuals with a BMI over 30 (or over 27 with weight-related comorbidities like hypertension or sleep apnea) whose health outcomes measurably improve with pharmacological intervention. When a 32-year-old seeking to lose fifteen pounds for a wedding uses the same drug as a 58-year-old with obesity-related cardiovascular disease, the risk-benefit calculus is fundamentally different. This matters for brain health in particular. Older adults considering GLP-1 medications — whether for weight management or because a family member suggested it — may not realize that the safety data overwhelmingly comes from populations with diagnosed obesity or diabetes. The further a patient’s profile drifts from the studied population, the less confidence anyone can have about outcomes.
How Loosened Prescribing Standards Are Fueling Off-Label Use
The regulatory landscape has quietly shifted in ways that make broader prescribing almost inevitable. Both Novo Nordisk and Eli Lilly removed specific BMI cutoffs from the FDA labels for Wegovy and Zepbound, leaving clinicians with considerable discretion. Simultaneously, the Lancet Commission on Diagnostic Criteria of Clinical Obesity has been pushing to move away from BMI-only diagnosis entirely, instead defining obesity based on gender, age, and body composition. While this is scientifically sound — BMI has well-documented limitations, particularly for older adults whose muscle mass naturally declines — it also creates a gray zone where prescribing decisions become more subjective. However, if you or a loved one is considering a GLP-1 medication without a clear obesity diagnosis, it is important to understand that broader labels do not mean broader safety evidence. The clinical trials that earned these drugs their FDA approvals were conducted on patients who met specific diagnostic criteria.
Removing BMI ranges from a label does not generate new safety data for people outside those original study populations. A 72-year-old with mild cognitive impairment and a BMI of 26 faces a very different physiological reality than the average trial participant. The risk of muscle loss — already a serious concern for aging brains and bodies — becomes even more pronounced in someone who was not carrying significant excess fat to begin with. The compounding pharmacy market adds another layer of concern. As of April 30, 2025, the FDA had received 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide. These compounded versions are not subject to the same manufacturing standards as brand-name drugs, yet they are often the most accessible option for patients who fall outside insurance coverage criteria. For older adults or their caregivers, sourcing medications from compounding pharmacies without close medical supervision introduces risks that are difficult to quantify.
The Muscle Loss Problem and Why It Matters for Brain Health
One of the most concerning aspects of GLP-1 use in non-obese patients is the pattern of body composition change. As NPR reported, users tend to lose muscle first but regain fat when stopping the drug, creating a yo-yo effect that can leave someone in worse metabolic shape than where they started. For older adults, this is not merely a cosmetic inconvenience — it is a direct threat to functional independence and cognitive health. Sarcopenia, the age-related loss of muscle mass and strength, is already linked to increased fall risk, reduced mobility, and faster cognitive decline. When a drug accelerates muscle loss in someone who did not have significant excess fat to lose, the downstream effects can be severe.
A 65-year-old who loses ten pounds of muscle and then regains that weight as fat after discontinuing the medication has fundamentally altered their body composition in a way that increases inflammation, insulin resistance, and frailty — all of which are risk factors for dementia. The persistence data underscores how common this cycle is. While one-year persistence on GLP-1s for weight loss nearly doubled from 33.2 percent in 2021 to 60.9 percent in the first half of 2024, three-year persistence dropped to just 8.1 percent. That means roughly 11 out of 12 patients stop the medication within three years. For the majority who quit, the muscle-then-fat rebound is not a theoretical risk — it is the expected outcome.
Insurance Barriers, Cost Pressures, and the Access Paradox
The economics of GLP-1 medications create a paradox that hits older adults and caregivers particularly hard. Insurance coverage has become more restrictive in some cases, with certain plans now requiring a BMI over 40 for weight loss drug coverage — even though obesity is clinically defined as starting at BMI 30. This means a patient with a BMI of 35 and genuine obesity-related health problems may face the same coverage denial as someone with a BMI of 24 seeking the drug for vanity reasons. The global prescription weight loss medications market is projected to reach $40.13 billion by 2035, and the broader anti-obesity drug market could hit $104.9 billion by 2035 at a compound annual growth rate of 18.3 percent.
These numbers reflect enormous commercial incentives to expand the user base well beyond the traditionally obese population. For patients and families, the tradeoff is stark: brand-name GLP-1s can cost over $1,000 per month without insurance, pushing cost-conscious patients toward compounded versions with less regulatory oversight, or toward stopping the medication abruptly — triggering the very rebound effects that make these drugs risky for non-obese users in the first place. For dementia caregivers managing a loved one’s medications, the addition of a GLP-1 to an already complex regimen introduces drug interaction questions, nutritional concerns from reduced appetite, and the logistical burden of injectable medications. These practical realities deserve as much weight as the clinical data when deciding whether a GLP-1 is appropriate for someone who does not have a clear medical indication.
Disordered Eating, Screening Gaps, and Unmonitored Side Effects
A risk that receives far too little attention in the GLP-1 conversation is the intersection with disordered eating. NPR reported that patients are often not screened for eating disorders before being prescribed these medications. For someone with a history of anorexia, bulimia, or binge eating disorder, a drug that dramatically suppresses appetite can reinforce harmful patterns rather than promote health. This screening gap is especially concerning in the telehealth-driven prescribing model, where a ten-minute video consultation may not surface a complex psychiatric history. The known side effects are significant even for patients without pre-existing eating disorders. Common adverse events include nausea, constipation, vomiting, and gallbladder disease.
Rare but serious complications include pancreatitis, kidney conditions, and thyroid cancer risk. For older adults, nausea and reduced appetite can quickly lead to dehydration and malnutrition — conditions that accelerate cognitive decline and increase hospitalization risk. Perhaps most important for anyone weighing these drugs: long-term side effects remain unstudied. Researchers at UChicago Medicine have warned that if large numbers of the general public use these drugs off-label, delayed adverse effects could emerge that were never captured in clinical trials. The trials that exist were designed around obese and diabetic populations over relatively short time horizons. Extending those results to non-obese patients taking the drugs for years is an assumption, not evidence.
Tirzepatide Versus Semaglutide — What the Head-to-Head Data Shows
For patients and caregivers trying to understand the GLP-1 landscape, the competition between the two dominant drugs matters. In head-to-head trials, tirzepatide was superior to semaglutide for body weight reduction and waist circumference at 72 weeks among participants with obesity but without diabetes. By September 2025, tirzepatide had overtaken semaglutide as the most commonly prescribed first-time GLP-1.
This does not mean tirzepatide is the better choice for every patient. Greater weight loss also means greater potential for muscle loss, and the comparative safety profiles in older adults or patients with cognitive impairment have not been specifically studied. A drug that produces more dramatic results in a 40-year-old clinical trial participant may behave very differently in a 70-year-old with polypharmacy and reduced kidney function.
What This Trend Means for Dementia Care Going Forward
The expansion of GLP-1 use beyond the obese population is not going to slow down. The commercial incentives are too large, the prescribing pathways too accessible, and the cultural appetite for pharmaceutical weight loss too strong. For the dementia care community, the relevant question is not whether these drugs will be used by people without obesity — they already are, by the millions — but how to ensure that older adults and cognitively vulnerable patients are not caught in a prescribing wave that was never designed with them in mind. Early research into GLP-1 receptor agonists and neuroprotection has generated genuine scientific interest, but that research is preliminary and focused on patients with metabolic disease.
Extrapolating those findings to justify GLP-1 prescriptions for brain health in non-obese older adults would be premature. Caregivers should insist on thorough medical evaluation, including body composition assessment and eating disorder screening, before any older adult in their care begins one of these medications. The cost of caution is small. The cost of getting it wrong — accelerated muscle loss, nutritional decline, or unmonitored drug interactions in a patient already fighting cognitive deterioration — is not.
Conclusion
The weight loss drug trend reaching patients without obesity diagnoses represents one of the most significant shifts in pharmaceutical prescribing in recent years. With one in four new GLP-1 users lacking a diabetes diagnosis, loosened FDA label language, and easy access through telehealth and compounding pharmacies, the drugs are reaching a population for whom the safety data is thin. The muscle loss and rebound pattern, the three-year persistence rate of just 8.1 percent, and the absence of long-term safety studies for off-label use all point to a drug class whose risks are being systematically underweighted against its benefits — particularly for non-obese users.
For families managing dementia care, the stakes are amplified. Muscle loss, malnutrition from appetite suppression, and unscreened interactions with existing medications can directly worsen cognitive and functional outcomes. Before adding a GLP-1 to any care plan, demand a comprehensive evaluation that goes beyond BMI, ask hard questions about what happens when the drug is eventually discontinued, and recognize that the loudest voices in this conversation are often the ones with $104.9 billion in projected market growth riding on the answer.
Frequently Asked Questions
Can GLP-1 medications help prevent or treat dementia?
There is early-stage research into the neuroprotective potential of GLP-1 receptor agonists, but no GLP-1 drug is approved or recommended for dementia prevention or treatment. The existing studies focus on patients with metabolic disease, and results should not be generalized to non-obese or cognitively impaired populations without further clinical evidence.
Is it safe for an older adult with mild cognitive impairment to take a GLP-1 for weight loss?
Safety depends on individual health factors including body composition, nutritional status, kidney function, and existing medications. The clinical trials supporting GLP-1 approval did not specifically study older adults with cognitive impairment. Any decision should involve a thorough evaluation by a physician familiar with the patient’s full medical history.
What happens when someone stops taking a GLP-1 medication?
Most patients regain weight after discontinuation, and the pattern tends to involve losing muscle during treatment but regaining fat afterward. Only about 1 in 12 patients remain on GLP-1 treatment at the three-year mark, making this rebound effect a common rather than exceptional outcome.
Are compounded versions of semaglutide and tirzepatide safe?
Compounded versions are not held to the same manufacturing standards as FDA-approved brand-name drugs. As of April 2025, the FDA had received 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide. Patients considering compounded versions should discuss the risks with their prescribing physician.
Why are insurance companies making it harder to get coverage for weight loss drugs?
Some insurers have raised BMI thresholds for coverage to BMI 40 or above, despite obesity being clinically defined at BMI 30. This is largely a cost-containment strategy in response to the rapid growth in GLP-1 prescriptions and the high monthly cost of these medications, which can exceed $1,000 without insurance.
